IL303686A - Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use - Google Patents

Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use

Info

Publication number
IL303686A
IL303686A IL303686A IL30368623A IL303686A IL 303686 A IL303686 A IL 303686A IL 303686 A IL303686 A IL 303686A IL 30368623 A IL30368623 A IL 30368623A IL 303686 A IL303686 A IL 303686A
Authority
IL
Israel
Prior art keywords
γglu
aib
isolated polypeptide
seq
spacer
Prior art date
Application number
IL303686A
Other languages
English (en)
Hebrew (he)
Original Assignee
I2O Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by I2O Therapeutics Inc filed Critical I2O Therapeutics Inc
Publication of IL303686A publication Critical patent/IL303686A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
IL303686A 2020-12-17 2021-12-16 Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use IL303686A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063126736P 2020-12-17 2020-12-17
PCT/US2021/063920 WO2022133148A1 (en) 2020-12-17 2021-12-16 Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use

Publications (1)

Publication Number Publication Date
IL303686A true IL303686A (en) 2023-08-01

Family

ID=80123475

Family Applications (1)

Application Number Title Priority Date Filing Date
IL303686A IL303686A (en) 2020-12-17 2021-12-16 Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use

Country Status (12)

Country Link
US (2) US12084485B2 (https=)
EP (1) EP4263587A1 (https=)
JP (1) JP2024502740A (https=)
KR (1) KR20230156689A (https=)
CN (1) CN116917311A (https=)
AR (1) AR124395A1 (https=)
AU (1) AU2021400738A1 (https=)
CA (1) CA3202389A1 (https=)
IL (1) IL303686A (https=)
MX (1) MX2023007224A (https=)
TW (1) TW202237628A (https=)
WO (1) WO2022133148A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3204051A1 (en) 2021-01-20 2022-07-28 Brian Lian Compositions and methods for the treatment of metabolic and liver disorders
JP7642830B2 (ja) 2021-09-15 2025-03-10 バイキング・セラピューティクス・インコーポレイテッド 代謝及び肝臓障害の処置のための組成物及び方法
IL322661A (en) * 2023-02-10 2025-10-01 Hangzhou Sciwind Biosciences Co Ltd Polypeptide and its history, composition containing them and their use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2200626A4 (en) * 2007-09-07 2012-02-15 Ipsen Pharma Sas ANALOGUE OF EXENDIN-4 AND EXENDIN-3
RU2547990C2 (ru) * 2009-09-28 2015-04-10 Интарсия Терапьютикс, Инк. Быстрое достижение и/или прекращение существенной стабильной доставки лекарственного средства
BR112014014898A2 (pt) * 2011-12-22 2020-10-27 Pfizer Inc. processo para purificar uma amostra de anticorpo h38c2, ou variante do mesmo, e composição compreendendo o referido h38c2
UA116217C2 (uk) * 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
KR102574993B1 (ko) * 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
MX2018014966A (es) * 2016-06-09 2019-08-14 Medimmune Ltd Peptidos monolipidados resistentes a proteasas.
CN111333714A (zh) * 2020-03-05 2020-06-26 成都奥达生物科技有限公司 一种长效glp-1化合物

Also Published As

Publication number Publication date
US20230063420A1 (en) 2023-03-02
US12084485B2 (en) 2024-09-10
KR20230156689A (ko) 2023-11-14
EP4263587A1 (en) 2023-10-25
AU2021400738A1 (en) 2023-07-13
JP2024502740A (ja) 2024-01-23
CA3202389A1 (en) 2022-06-23
TW202237628A (zh) 2022-10-01
US20250034225A1 (en) 2025-01-30
AR124395A1 (es) 2023-03-22
CN116917311A (zh) 2023-10-20
MX2023007224A (es) 2023-09-05
WO2022133148A1 (en) 2022-06-23

Similar Documents

Publication Publication Date Title
JP7636321B2 (ja) ヒトアミリンアナログペプチド及び使用方法
IL262802B2 (en) Glucagon receptor selective polypeptides and methods of using them
IL297375A (en) Controlled-release cnp agonists with low npr–c binding
US12122816B2 (en) Long acting peptide tyrosine tyrosine (PYY) analogs and methods of use
US20250034225A1 (en) Long acting glucagon like polypeptide-1 (glp-1) receptor agonists and methods of use
WO2017200944A1 (en) Glucagon receptor/glp-1 receptor selective analog polypeptides and methods of use thereof
US20240228572A1 (en) Long acting glucagon receptor selective peptides and methods of use
CA3116023C (en) Human amylin analog polypeptides and methods of use
RU2839688C2 (ru) Полипептиды аналога амилина человека и способы их применения
EA052603B1 (ru) Селективные к рецептору глюкагона пептиды длительного действия и способы их применения